Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

282 trials

NCT07609862
Recruiting
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Phase 1/2 · China · 1 site
Registry update: 30 Jul 2026
NCT07570017
Recruiting
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase 1 · China · 2 sites
Registry update: 10 Sept 2026
NCT07691606
Recruiting
A Study of ARC-02 in B-cell NHL
Phase 1 · Australia, Spain, France, Italy, Poland, United States · 28 sites
Registry update: 2 Nov 2026
NCT07507318
Recruiting
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
Phase 2 · China · 1 site
Registry update: 18 Jun 2026
NCT07570823
Recruiting
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 3 · China · 1 site
Registry update: 13 Aug 2026
NCT06594939
Recruiting
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
Phase 2 · United States · 1 site
Registry update: 25 Aug 2026
NCT07528352
Recruiting
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
Phase 1 · United States · 1 site
Registry update: 4 Jun 2026
NCT07608978
Recruiting
Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
Phase 2 · China · 1 site
Registry update: 27 May 2026
NCT07493109
Recruiting
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
Phase 3 · China · 1 site
Registry update: 25 Mar 2026
NCT07478848
Recruiting
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
Phase 1 · United States · 1 site
Registry update: 1 Jul 2026
NCT07817641
Recruiting
Proton Therapy for Mediastinal Lymphoma (PROMLY)
Not applicable · Denmark · 1 site
Registry update: 14 Sept 2026
NCT07493148
Recruiting
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Phase 2 · China · 1 site
Registry update: 25 Mar 2026
NCT07548697
Recruiting
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
Early phase 1 · China · 1 site
Registry update: 23 Apr 2026
NCT07226843
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Phase 1 · Germany, Spain, France, United Kingdom, Italy, Japan, Poland, United States · 45 sites
Registry update: 4 Nov 2026
NCT07249905
Recruiting
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Phase 1/2 · Australia, Spain, Israel · 7 sites
Registry update: 6 Nov 2026
NCT07523737
Recruiting
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Phase 2 · China · 1 site
Registry update: 15 Apr 2026
NCT07409428
Recruiting
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Phase 3 · China · 50 sites
Registry update: 20 Jul 2026
NCT07739654
Recruiting
Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma.
Phase 3 · Pakistan · 1 site
Registry update: 10 Aug 2026
NCT07451652
Recruiting
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Phase 2 · Mexico · 1 site
Registry update: 1 Apr 2026
2025-521205-41-00
Recruiting
A Randomized, placebo-controlled, double-blinded Phase 2 Trial of Dapagliflozin for Preventing Treatment-associated Cardiotoxicity in Lymphoma
Phase 2 · Denmark · 6 sites
Registry update: 6 Nov 2026

Ordered by registry start date. Freshness and sponsorship never change the order.